PL1626721T3 - Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju - Google Patents

Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju

Info

Publication number
PL1626721T3
PL1626721T3 PL04785621T PL04785621T PL1626721T3 PL 1626721 T3 PL1626721 T3 PL 1626721T3 PL 04785621 T PL04785621 T PL 04785621T PL 04785621 T PL04785621 T PL 04785621T PL 1626721 T3 PL1626721 T3 PL 1626721T3
Authority
PL
Poland
Prior art keywords
mood
treating
stabilizers
carbostyril derivatives
disorders
Prior art date
Application number
PL04785621T
Other languages
English (en)
Inventor
Tetsuro Kikuchi
Taro Iwamoto
Tsuyoshi Hirose
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33490596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1626721(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of PL1626721T3 publication Critical patent/PL1626721T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PL04785621T 2003-05-23 2004-05-19 Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju PL1626721T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47337803P 2003-05-23 2003-05-23
PCT/US2004/013308 WO2004105682A2 (en) 2003-05-23 2004-05-19 Carbostyril derivatives and mood stabilizers for treating mood disorders

Publications (1)

Publication Number Publication Date
PL1626721T3 true PL1626721T3 (pl) 2017-05-31

Family

ID=33490596

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04785621T PL1626721T3 (pl) 2003-05-23 2004-05-19 Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju

Country Status (27)

Country Link
US (5) US9125939B2 (pl)
EP (2) EP2601953A1 (pl)
JP (2) JP4693778B2 (pl)
KR (1) KR100881046B1 (pl)
CN (5) CN102166359A (pl)
AU (1) AU2004243096B2 (pl)
BR (1) BRPI0410786A (pl)
CA (1) CA2526562C (pl)
CO (1) CO5630025A2 (pl)
CY (1) CY1118313T1 (pl)
DK (1) DK1626721T3 (pl)
EC (1) ECSP056182A (pl)
ES (1) ES2609382T3 (pl)
GE (1) GEP20084567B (pl)
HU (1) HUE030014T2 (pl)
IL (3) IL171414A (pl)
LT (1) LT1626721T (pl)
MX (1) MXPA05012538A (pl)
NO (1) NO332764B1 (pl)
NZ (1) NZ542985A (pl)
PL (1) PL1626721T3 (pl)
PT (1) PT1626721T (pl)
RU (1) RU2359675C2 (pl)
TW (1) TWI342776B (pl)
UA (1) UA92453C2 (pl)
WO (1) WO2004105682A2 (pl)
ZA (1) ZA200508306B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
KR100842694B1 (ko) 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
CN101111245A (zh) 2005-01-27 2008-01-23 阿雷姆贝克有限公司 左乙拉西坦延长释放制剂
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AU2006274263B2 (en) 2005-07-26 2011-01-27 Ucb Pharma, S.A. Pharmaceutical compositions comprising levetiracetam and process for their preparation
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
NZ595263A (en) * 2009-02-26 2013-06-28 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
EP2672822A4 (en) * 2011-02-09 2014-08-27 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
ES2765036T3 (es) 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden esteres de ácidos grasos
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
CN103550778B (zh) * 2013-11-18 2015-12-30 四川科瑞德制药有限公司 一种治疗情感性精神障碍疾病的药物组合物
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN108623520A (zh) * 2017-03-16 2018-10-09 重庆医药工业研究院有限责任公司 阿立哌唑缩醛月桂酸酯的制备方法
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
US20240009181A1 (en) * 2022-07-08 2024-01-11 Jason Eric Schiffman Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same
CN115991674B (zh) * 2022-12-14 2025-03-18 杭州同舟生物技术有限公司 一种阿立哌唑人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JPH04284524A (ja) * 1991-03-14 1992-10-09 Matsushita Electric Ind Co Ltd キー入力装置
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
US20030027817A1 (en) 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
BR9911068A (pt) 1998-05-29 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de distúrbios bipolares
ATE294577T1 (de) 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
CA2363942A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
JP2004527553A (ja) * 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1480629A1 (en) * 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
KR100842694B1 (ko) * 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines

Also Published As

Publication number Publication date
NZ542985A (en) 2009-04-30
ECSP056182A (es) 2006-04-19
ES2609382T3 (es) 2017-04-20
EP1626721B1 (en) 2016-12-07
ZA200508306B (en) 2007-03-28
CO5630025A2 (es) 2006-04-28
CN102172401A (zh) 2011-09-07
US20210308126A1 (en) 2021-10-07
US9125939B2 (en) 2015-09-08
CY1118313T1 (el) 2017-06-28
US20070031513A1 (en) 2007-02-08
JP2011093920A (ja) 2011-05-12
BRPI0410786A (pt) 2006-06-20
DK1626721T3 (en) 2017-01-23
CA2526562A1 (en) 2004-12-09
JP4693778B2 (ja) 2011-06-01
MXPA05012538A (es) 2006-02-22
KR100881046B1 (ko) 2009-01-30
PT1626721T (pt) 2017-02-28
TW200426146A (en) 2004-12-01
EP1626721A4 (en) 2008-06-18
WO2004105682A3 (en) 2005-05-12
AU2004243096A1 (en) 2004-12-09
US20200246332A1 (en) 2020-08-06
HUE030014T2 (en) 2017-04-28
EP1626721A2 (en) 2006-02-22
KR20060021857A (ko) 2006-03-08
NO20055152D0 (no) 2005-11-03
RU2359675C2 (ru) 2009-06-27
CN102000336A (zh) 2011-04-06
US20240024310A1 (en) 2024-01-25
CN102166359A (zh) 2011-08-31
JP2007503460A (ja) 2007-02-22
TWI342776B (en) 2011-06-01
EP2601953A1 (en) 2013-06-12
CN102172402A (zh) 2011-09-07
LT1626721T (lt) 2017-01-25
WO2004105682A2 (en) 2004-12-09
IL211529A0 (en) 2011-05-31
CN1794994A (zh) 2006-06-28
NO20055152L (no) 2005-12-07
RU2005140285A (ru) 2006-06-10
IL230025A0 (en) 2014-01-30
UA92453C2 (ru) 2010-11-10
GEP20084567B (en) 2008-12-25
IL171414A (en) 2015-03-31
NO332764B1 (no) 2013-01-07
CA2526562C (en) 2011-06-28
AU2004243096B2 (en) 2008-12-18
US20160030423A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
IL230025A0 (en) Carbosteril history and mood stabilizers for the treatment of mood disorder
PL371492A1 (pl) Pochodne chinolinonu przeznaczone do leczenia chorób związanych z proliferacją komórek
IL188988A0 (en) Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
IL249389A0 (en) Combined therapy for the treatment of disorders associated with protein deficiency
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
TWI339585B (en) Compositions and methods for treating coagulation related disorders
AP2007003891A0 (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-pipe ridine derivatives as pde10 inhibitors for the treatment of cns disorders
WO2005046434A8 (en) Compositions and methods for diagnosing and treating mental disorders
PL1599467T3 (pl) Nowe pochodne cyjanopirydyny użyteczne w leczeniu raka i innych zaburzeń
ZA200610661B (en) Compositions and methods for treating neurological disorders
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL179864A0 (en) Compounds and methods for treating seizure and paroxysmal disorders
EP1567198A4 (en) MATERIALS AND METHOD FOR THE TREATMENT OF EYE DISEASES
ZA200600176B (en) Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
IL169358A0 (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
IL175610A0 (en) Methods and reagents for the treatment of inflammatory disorders
TWI315669B (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
ZA200610474B (en) Compositions and methods for treating inflammatory disorders
AU2003297259A8 (en) Methods and compositions for treating neurological disorders
ZA200704412B (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
AU2003216501A8 (en) Methods of treating pin1 associated disorders
HK1088825A (en) Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss